Circular RNA Expression Profiles in Plasma from Patients with Heart Failure Related to Platelet Activity.

Yeying Sun,Bingrui Zhao,Chunxiang Zhang,Weihua Bian,Jing Jiang,Xiaoli Jiang,Xinyue Liang,Yan Lv,Daolai Zhang

doi:10.3390/biom10020187

Yeying Sun, Bingrui Zhao + Show 7 more

Open Access

https://doi.org/10.3390/biom10020187

Copy DOI

Journal: Biomolecules	Publication Date: Jan 25, 2020
Citations: 33	License type: CC BY 4.0

Affiliation: Binzhou University, Binzhou Medical University

Abstract

Heart failure (HF) is a deadly disease that is difficult to accurately diagnose. Circular RNAs (circRNAs) are a novel class of noncoding RNAs that might play important roles in many cardiovascular diseases. However, their role in HF remains unclear. CircRNA microarrays were performed on plasma samples obtained from three patients with HF and three healthy controls. The profiling results were validated by quantitative reverse transcription polymerase chain reaction. The diagnostic value of circRNAs for HF was evaluated by receiver operating characteristic (ROC) curves. The expression profiles indicated that 477 circRNAs were upregulated and 219 were downregulated in the plasma of patients with HF compared with healthy controls. Among the dysregulated circRNAs, hsa_circ_0112085 (p = 0.0032), hsa_circ_0062960 (p = 0.0006), hsa_circ_0053919 (p = 0.0074) and hsa_circ_0014010 (p = 0.025) showed significantly higher expression in patients with HF compared with healthy controls. The area under the ROC curve for hsa_circ_0062960 for HF diagnosis was 0.838 (p < 0.0001). Correlation analysis showed that the expression of hsa_circ_0062960 was highly correlated with B-type natriuretic peptide (BNP) serum levels. Some differential circRNAs were found to be related to platelet activity by Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses. The landscape of circRNA expression profiles may play a role in HF pathogenesis and improve our understanding of platelet function in HF. Moreover, hsa_circ_0062960 has potential as a novel diagnostic biomarker for HF.

Highlights

Heart failure (HF), often known as congestive HF, occurs when the heart fails to properly pump sufficient blood to the whole body
Given that B-Type natriuretic peptide (BNP) is involved in several physiological processes, the expression levels of plasma BNP or NT-proBNP are affected by aging, gender, and some cardiac function and endocrine diseases, such as hyperthyroidism [8,9]
Four stages of HF were identified according to the guidelines of New York Heart Association (NYHA) functional classification by cardiologists specialized in HF

Summary

Introduction

Heart failure (HF), often known as congestive HF, occurs when the heart fails to properly pump sufficient blood to the whole body. B-Type natriuretic peptide (BNP) or N-terminal pro BNP (NT-proBNP) is a widely used biomarker in HF and is primarily used to help detect, diagnose, and evaluate the severity of HF [5,6,7]. Given that BNP is involved in several physiological processes, the expression levels of plasma BNP or NT-proBNP are affected by aging, gender, and some cardiac function and endocrine diseases, such as hyperthyroidism [8,9]. BNP levels may be altered by some drugs, such as angiotensin-converting enzyme inhibitors and diuretics, which increase fluid loss [9]. These potential factors may influence the accurate diagnosis of HF.

Methods

Results

Conclusion